Eli Khankin
Director Apellis Pharmaceuticals
Seminars
Wednesday 18th March 2026
Clinical Pathway to Registration: First Treatment for C3 Glomerulopathy (C3G) & Primary IC-MPGN in Patients 12+
8:00 am
- Achieving regulatory approval by demonstrating efficacy across all three key disease markers: 68% reduction in proteinuria, kidney function stabilization, and substantial C3 deposit clearance.
- Establishing a broad label covering adults and adolescents with C3G or primary ICMPGN, including post-transplant C3G recurrence
- Building a well-characterized safety profile supported by >2,200 patient-years of experience in approved indications
- Providing a model for rare kidney disease development, addressing conditions with high risk of progression to kidney failure
